InterVenn: Funding, Investors & Team (Oct 2026)
InterVenn focuses on the identification, quantification, and classification of Glycoproteomic and other PTM signals found in human blood and tissue for biomarker and target discovery. It specializes in the fields of biotechnology and life science. The company's VISTA is the first commercially available platform that can assess (serum or plasma) protein glycosylation in a site-specific manner, across thousands of peptides and glycopeptides. It was founded in 2017 and headquartered in Redwood City, California.
InterVenn has raised $201M across 1 funding round on record, the most recent a Series C of $201M announced in Aug 2021.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
InterVenn Company Profile and Key Stats
Latest funding round on record: Aug 2021.
InterVenn Funding Rounds
InterVenn Founders and Leadership Team
Contact details for the InterVenn team: 1 of 1 has an email address on file.
Start 14-day free trial →InterVenn Funding Compared to Other Biotechnology Startups
InterVenn's latest round of $201M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like InterVenn in Biotechnology and South San Francisco
Companies Similar to InterVenn
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
InterVenn Funding FAQs
What does InterVenn do?
InterVenn focuses on the identification, quantification, and classification of Glycoproteomic and other PTM signals found in human blood and tissue for biomarker and target discovery. It specializes in the fields of biotechnology and life science. The company's VISTA is the first commercially available platform that can assess (serum or plasma) protein glycosylation in a site-specific manner, across thousands of peptides and glycopeptides. It was founded in 2017 and headquartered in Redwood City, California.
How much funding has InterVenn raised?
InterVenn has raised $201M across 1 round on record. The most recent is a Series C of $201M announced in Aug 2021.
When did InterVenn last raise funding?
InterVenn's most recent funding round on record is a Series C of $201M, announced in Aug 2021.
Who is the CEO of InterVenn?
Aldo Carrascoso is listed as CEO at InterVenn.
Where is InterVenn headquartered?
InterVenn is based in South San Francisco, California, United States.
How many employees does InterVenn have?
InterVenn is in the 101-250 employee band.
How does InterVenn's funding compare to other Biotechnology startups?
InterVenn's latest round of $201M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's InterVenn Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for InterVenn is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.